Fans of biotech bigwig Genentech ( DNA) are hoping big sales of Avastin and Lucentis will carry the day as the company reports fourth-quarter results after the close. Analysts say Avastin, the company's highly touted colorectal cancer drug, could see a boost from strong sales growth as a nonsmall-cell lung cancer treatment. "Avastin use in nonsmall-cell lung cancer is on pace to grow quarter over quarter by over 50% vs. our prior estimate of 25%," says Rodman & Renshaw analyst Michael King. In October, Avastin received a new Food and Drug Administration approval as a first-choice treatment for nonsmall-cell lung cancer in a combination with chemotherapy drugs. Based on recent cancer treatment regimens and sales trends noted by drug market research firm IMS Health, King raised his Avastin sales estimates to $485 million from the $465 million he previously expected. King says sales of Genentech's eye drug Lucentis could blow past consensus estimates of $152 million, reaching $204 million. The analyst previously expected Lucentis sales of $169 million, and says results could still exceed his higher target. Even before its launch in the third quarter, Lucentis was touted by researchers as the most effective treatment for macular degeneration. Unlike its competitors -- Visudyne sold by Novartis ( NVS) and Macugen from OSI Pharmaceuticals ( OSIP) -- Lucentis not only slowed or stopped vision loss, it actually improved vision in a number of patients.